 GAINESVILLE, Fla., and CAMBRIDGE, Mass., Sept. 01, 2022 GLOBE NEWSWIRE -- Applied Genetic Technologies Corporation AGTC or the Company Nasdaq: AGTC, a clinical-stage biotechnology company focused on the development and potential commercialization of adeno-associated virus AAV-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases, today announced that management will be participating in the following investor conferences: 